Antibody Blocking Constructs for Localized Antigen Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing antibodies are in an active state under normal physiological conditions, leading to unintended binding throughout the body and causing life-threatening side effects, and there is a lack of commercially available binding proteins that can irreversibly anchor to a specific attachment site near the antigen binding site of antibodies.
Innovation Solution
Development of blocking constructs that utilize crosslinker kappa light chain-binding domains, such as Protein L with photo-reactive residues, to crosslink with antibodies, allowing for spatial and temporal control of binding activity through photo-cleavable or enzymatically cleavable connections to the antigen binding site.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies are infused in their active state to induce immune activation, then therapeutic effect is improved, but side effects worsen due to unintended binding throughout the body
Solution Approach 1:
The patent applies preliminary action by pre-conjugating blocking moieties to antibodies before administration, creating blocked immunoglobulin complexes that are ready for controlled activation. The blocking moieties are attached via cleavable linkers that remain intact during circulation, ensuring the antibody stays inactive until it reaches the target site where specific conditions trigger cleavage and activation.
Solution Approach 2:
The patent uses blocking moieties as intermediaries that temporarily prevent antibody-antigen binding. These blocking moieties are conjugated to the antibody via cleavable linkers, creating an intermediate blocked state. At the target site, specific conditions (proteases, pH changes, or photoactivation) trigger the release of the blocking moiety, allowing the antibody to activate and bind its target, thus mediating the transition from inactive to active state.
2Manufacturing precision
If site-specific labeling methods are used to attach blocking moieties, then conjugation precision is improved, but labeling consistency worsens due to variable numbers of labels at multiple locations
Solution Approach 1:
The patent extracts the labeling step from the conjugation process by providing pre-formed blocking constructs that already contain the blocking moiety attached to a cleavable linker. This separation allows site-specific attachment of the blocking construct to the antibody without worrying about variable labeling at multiple locations, as the blocking moiety is pre-positioned on the construct rather than being randomly attached to the antibody.
Solution Approach 2:
The patent introduces a blocking construct as an intermediary molecule that contains both the blocking moiety and the cleavable linker. This construct serves as a pre-assembled unit that attaches to the antibody at a specific site, ensuring consistent and controlled conjugation. The intermediary construct mediates between the blocking moiety and the antibody, providing a standardized interface for attachment.
3Ease of manufacture
If conventional binding proteins are used for conjugation, then attachment capability is improved, but spatial control worsens because attachment sites are not located in proximity to the antigen binding site
Solution Approach 1:
The patent applies local quality by designing blocking constructs with specific structural features that enable attachment at defined locations on the antibody. The constructs are engineered to bind to specific regions (such as the Fc region or Fab region) that are in proximity to the antigen binding site, ensuring that the blocking moiety is positioned optimally to interfere with antigen binding while allowing for controlled release.
4Reliability
If genetic fusion of capping peptides is used to block antibody binding, then binding control is improved, but manufacturing complexity worsens due to requirement for genetic modification and specialized expression systems
Solution Approach 1:
The patent uses copying by providing blocking constructs that can be synthesized chemically or produced in standard expression systems, rather than requiring genetic modification of the antibody itself. The blocking construct contains a copy of the blocking function that can be attached to the antibody through well-established conjugation chemistries, avoiding the need for specialized genetic engineering facilities and procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables localized antibody binding by transitioning from a non-binding 'off-state' to a binding 'on-state' with precise control, reducing side effects and enhancing therapeutic efficacy.
Implementation Method 1
at least one amino acid residue in the Protein L amino acid sequence is substituted by a photo-reactive crosslinker residue having an activation wavelength
Implementation Method 2
the cleavable linker is cleaved by a specific trigger, such as an enzyme or light
Implementation Method 3
photo-cleavable or enzymatically cleavable connections to the antigen binding site
Data Source
AI summary
The present disclosure describes compositions, kits and methods for immunoglobulin blocking constructs that may be crosslinked to immunoglobulins to form blocked immunoglobulin complexes useful for selectively modulating the native binding activity of immunoglobulins and enhancing their utility as research tools and therapeutic treatments. Further, wherein a blocking construct for modulating binding activity of an antigen binding domain is disclosed.